FOI release

BUPRENORPHINE

Some or all of the information requested was not provided because we didn't hold it.

Case reference FOI2025/00770

Received 24 July 2025

Published 9 September 2025

Request

SCENARIO: A patient hands in a blue prescription listing only buprenorphine sublingual tablets (NOT SC), of which are not to be prescribed via supervised consumption only nor on a daily basis, with regard for the provision (via legal requirement) by the pharmacist [and not legal status of the drug itself A) What are (if any) the statutory/legislative/MHRC/ requirements that mandate by law, a pharmacist or pharmacy premises' to: do anything else different than they would otherwise when dispensing that medicine underlined above? B) What are (if any) the statutory/legislative/MHRC requirements that mandate by law, a pharmacist or pharmacy premises' to: override or disregard a disabled patients standing reasonable adjustments under the Equality Act 2010? C) What are (if any) the statutory/legislative/MHRC requirements that mandate by law, a pharmacist or pharmacy premises' to REQUIRE a collecting party to get a note, and within the note, confirmation from a "Key Worker" that confirms both: I. The fact that the patient's representative is to collect the patient's medication on that patient's behalf Ii. WHY the patient requires it collecting for them, and why they therefore cannot collect it themselves

Response

See attached

Documents

• FOI2025_00770 (redacted).pdf (641.3 KB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.